A Randomized Phase II Trial of Triplet Therapy (A PDL1 Inhibitor Durvalumab (MEDI4736) in Combination with Olaparib and Cediranib) Compared to Olaparib and Cediranib or Durvalumab (MEDI4736) and Cediranib or Standard of Care Chemotherapy in Women with Platinum Resistant Recurrent Epithelial Ovarian Cancer, Primary Peritoneal or Fallopian Cancer Who Have Received Prior Bevacizumab
For more information about the trial above please contact the study team:
Principal Investigator, Whitney Graybill, at firstname.lastname@example.org.
Study Coordinator, Michelle E Jones, at email@example.com.
Trial opened at the following institutions: Medical University of South Carolina